3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Gastrointestinal Stromal Tumors
17
Sarcoma
6
Sarcoma, Ewing
5
Osteosarcoma
5
Neoplasm Metastasis
4
Rhabdomyosarcoma
3
Colorectal Neoplasms
3
Mesothelioma, Malignant
2
Hemangiosarcoma
2
Chondrosarcoma
2
Bone Neoplasms
2
Wilms Tumor
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Gemcitabine
5
Docetaxel
4
tislelizumab
3
Bortezomib
3
spartalizumab
2
pembrolizumab
2
Nivolumab
2
Irinotecan
2
Filgrastim
2
Cisplatin
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
tinostamustine
1
talazoparib
1
surufatinib
1
regorafenib
1
pazopanib
1
pamiparib
1
liposomal doxorubicin
1
isophosphamide mustard
1
futibatinib
1
etoposide phosphate
1
entinostat
1
cc-486
1
cabozantinib
1
atezolizumab
1
anlotinib
1
Vinorelbine
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
regorafenib
×
Sarcoma
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn